آزمون آزمایشی OET Reading شماره 3

Text A: Epidemiology of Diabetes

Diabetes mellitus affects over 557 million adults globally, with type 2 diabetes (T2D) accounting for 93–95% of cases, according to International Diabetes Federation (IDF). Prevalence is surging in low- and middle-income countries, fueled by rising obesity, sedentary lifestyles, and aging populations. South Asia and Western Pacific report highest rates, with some nations exceeding 30% prevalence. Type 1 diabetes (T1D), an autoimmune condition, primarily affects children and young adults, necessitating lifelong insulin therapy. Key risk factors for T2D include genetic predisposition, poor diet, and physical inactivity, while T1D is less preventable. Complications such as retinopathy, neuropathy, and cardiovascular disease contribute to significant morbidity and mortality. The IDF projects 783 million cases by 2045, emphasizing urgent need for enhanced screening, public health campaigns, and prevention programs to curb this global epidemic.

Text B: Clinical Presentation

Diabetes presents with symptoms such as polyuria, polydipsia, fatigue, and unexplained weight loss, though T2D may remain asymptomatic for years, delaying diagnosis. T1D often manifests acutely, with diabetic ketoacidosis in severe cases, requiring immediate insulin administration to prevent life-threatening complications. T2D symptoms develop gradually, often identified through routine screening in primary care settings. Chronic hyperglycemia leads to serious complications, including cardiovascular disease (accounting for 50% of diabetes-related deaths), kidney failure, and lower-limb amputations due to neuropathy. Glycated hemoglobin (HbA1c) levels above 6.5% or fasting plasma glucose (FPG) ≥126 mg/dL confirm diagnosis. Regular monitoring and patient education on self-management are critical to prevent complications. Early lifestyle interventions in T2D, such as dietary changes and exercise, can significantly delay disease progression and improve long-term outcomes.

Text C: Diagnostic Methods

Diagnosing diabetes relies on blood tests to measure glucose levels. Fasting plasma glucose (FPG) ≥126 mg/dL, HbA1c ≥6.5%, or random plasma glucose ≥200 mg/dL with symptoms confirm condition. Oral glucose tolerance tests (OGTT) are employed when initial results are inconclusive, particularly in gestational diabetes. Screening is recommended for adults over 45, or younger individuals with risk factors like obesity, hypertension, or family history. Point-of-care HbA1c testing enables rapid diagnosis in primary care, improving access. Continuous glucose monitoring (CGM) is increasingly used in T1D to track real-time glucose trends and adjust insulin doses. The American Diabetes Association (ADA) advocates annual screening for high-risk groups to facilitate early intervention, reduce complications, and improve patient outcomes through timely management.

Text D: Treatment Approaches

T1D treatment requires insulin therapy, delivered via multiple daily injections or continuous subcutaneous insulin infusion pumps, tailored to individual glucose levels. T2D management begins with lifestyle modifications, including balanced diet and regular exercise, alongside metformin as first-line drug. If glycemic control is inadequate, sulfonylureas, DPP-4 inhibitors, or GLP-1 receptor agonists may be added, with insulin for advanced cases. The ADA recommends HbA1c targets below 7% to minimize complications. Bariatric surgery offers remission in 30–60% of obese T2D patients. Emerging therapies, such as SGLT2 inhibitors, reduce cardiovascular and renal risks. Multidisciplinary teams, including endocrinologists and dietitians, enhance outcomes through coordinated care. Patient adherence and regular follow-up are essential for treatment success and long-term health.

Text 1: Nursing Staff Memo

Subject: Improving Hand Hygiene Compliance

To: All Nursing Staff

From: Infection Control Team

Date: June 8, 2025

Recent audits reveal hand hygiene compliance at 72%, below hospital's 85% target. Non-compliance increases healthcare-associated infections (HAIs), endangering patient safety and prolonging hospital stays. Nurses must use alcohol-based hand rubs or soap and water before and after patient contact, following WHO guidelines. Unannounced audits will begin June 15 to monitor compliance. Staff achieving 90% compliance will be recognized in monthly newsletter. Training on hand hygiene techniques is scheduled for June 10–12; register via intranet by June 9. Non-attendance may impact performance reviews. Contact Infection Control Team (ext. 410) for resources or to address concerns.

Text 2: Pharmacy Policy Update

Subject: Safe Disposal of Expired Medications

To: Pharmacy Staff

From: Pharmacy Manager

Date: June 1, 2025

New regulations mandate enhanced disposal of expired or unused medications to prevent misuse and environmental contamination. Pharmacy staff must segregate expired drugs into designated bins for high-temperature incineration, ensuring no medications enter regular waste streams. Patients can return unused drugs through take-back program, launching June 10. All disposals must be logged in electronic system by June 30 to comply with regulatory audits. Mandatory training on disposal protocols is scheduled for June 5, with quarterly refreshers. Non-compliance risks fines or license suspension. Contact Pharmacy Manager (ext. 520) for clarification or additional support.

Text 3: Physiotherapy Department Notice

Subject: Updated Fall Prevention Guidelines

To: Physiotherapy Staff

From: Rehabilitation Services

Date: June 4, 2025

Falls among elderly inpatients increased by 15% in 2024, necessitating revised fall prevention protocols. Physiotherapists must assess patients' balance and mobility within 24 hours of admission using Berg Balance Scale. High-risk patients require tailored exercise plans focusing on strength and coordination. Walking aids must be correctly fitted, and patients educated on safe movement techniques. Compliance audits begin June 15. Mandatory training on new guidelines is scheduled for June 7; register by June 5 via staff portal. Non-compliance may jeopardize accreditation. Contact Rehabilitation Services (ext. 630) for resources or scheduling concerns.

Text 4: Public Health Advisory

Subject: Influenza Vaccination Campaign

To: Community Health Workers

From: Public Health Agency

Date: June 3, 2025

The 2025 influenza season is expected to be severe, with early cases reported. Vaccination, reducing hospitalization by 40% per CDC data, is primary prevention strategy. Prioritize high-risk groups: elderly, pregnant women, and those with chronic conditions. Administer quadrivalent vaccine, ensuring two doses for children under 9 receiving it for the first time. Free vaccines will be available at community clinics from June 10. Health workers must promote uptake, educate on side effects, and report vaccination data by July 15. Contact Public Health Agency (ext. 740) for promotional materials.

Text 5: Mental Health Protocol Update

Subject: Suicide Risk Assessment Guidelines

To: Mental Health Staff

From: Psychiatry Department

Date: June 6, 2025

New guidelines mandate suicide risk assessments for patients with depression or anxiety, using Columbia-Suicide Severity Rating Scale (C-SSRS) during initial consultations. High-risk patients must be referred to a psychiatrist within 48 hours and closely monitored. Assessments must be documented in electronic health record by June 30 to comply with audits. Mandatory training on C-SSRS is scheduled for June 9; register by June 7. Non-compliance may lead to disciplinary action. Contact Psychiatry Department (ext. 850) for resources or support.

Text 6: Dental Clinic Bulletin

Subject: Updated Infection Control Protocols

To: Dental Staff

From: Dental Services Manager

Date: June 7, 2025

Recent oral infection outbreaks highlight need for enhanced infection control. Dental staff must sterilize instruments using autoclaves and use disposable barriers for all procedures. Patients must rinse with chlorhexidine mouthwash before treatment to reduce microbial load. Compliance audits start June 15. Training on new protocols is mandatory, scheduled for June 11; register by June 9 via staff portal. Non-compliance risks patient safety and clinic accreditation. Contact Dental Services Manager (ext. 960) for guidelines or support.

Text 1: Non-Pharmacological Interventions for Dementia Care

Authors: Emily R. Thompson, Ph.D., et al.

Published: June 5, 2025, Lancet Neurol

Dementia affects 55 million people globally, with Alzheimer's disease (AD) accounting for 60–70% of cases. Non-pharmacological interventions (NPIs) like cognitive stimulation therapy (CST) and music therapy are gaining attention for improving quality of life (QoL) in dementia patients. These interventions aim to enhance cognitive function, reduce agitation, and support caregiver well-being, addressing limitations of pharmacological treatments, which often have side effects like sedation. The DEMCARE trial evaluated NPIs' efficacy in community-dwelling AD patients, focusing on sustainable, scalable approaches to support aging populations.

The DEMCARE trial was a randomized controlled trial involving 412 AD patients (mean age 78.3 years) across UK. Participants received either CST (14 sessions over 7 weeks, focusing on memory and problem-solving) plus music therapy (weekly group singing) or standard care (social activities without structured interventions). The primary outcome was QoL, measured by Quality of Life in Alzheimer's Disease (QoL-AD) scale (range 13–52). Secondary outcomes included agitation (Cohen-Mansfield Agitation Inventory, CMAI), cognitive function (Mini-Mental State Examination, MMSE), and caregiver burden (Zarit Burden Interview, ZBI).

At 6 months, the intervention group showed a significant QoL-AD improvement (mean difference 3.2 points; 95% CI, 1.8–4.6; P=0.002) compared to standard care. Agitation decreased significantly (CMAI mean difference −5.1; 95% CI, −8.3 to −1.9; P=0.008), with fewer behavioral disturbances. Cognitive function (MMSE) showed no significant change (mean difference 0.4; 95% CI, −0.7 to 1.5; P=0.47), suggesting NPIs primarily benefit emotional well-being. Caregiver burden reduced slightly (ZBI mean difference −2.8; 95% CI, −5.4 to −0.2; P=0.03), indicating secondary benefits.

Adverse events were minimal, with 2.1% of intervention participants reporting mild fatigue vs. 1.8% in standard care. No serious adverse events were linked to NPIs. The intervention's group-based delivery enhanced social engagement, potentially contributing to outcomes. Cost-effectiveness analysis showed an incremental cost of £320 per QoL-AD point gained, below UK's £30,000 per quality-adjusted life year threshold, supporting scalability.

Subgroup analyses indicated greater QoL benefits in mild AD (MMSE ≥20; mean difference 4.1; 95% CI, 2.3–5.9) than moderate AD (MMSE 10–19; mean difference 2.0; 95% CI, 0.5–3.5). Women showed slightly higher responsiveness (mean difference 3.8 vs. 2.5 for men), possibly due to social engagement preferences. Small subgroup sizes limit generalizability, warranting further research.

Strengths include trial's robust design and community focus, ensuring real-world applicability. Limitations include short follow-up (6 months) and lack of severe AD patients (MMSE <10), who may respond differently. The intervention's success relies on trained facilitators, posing implementation challenges in low-resource settings. Future studies should explore long-term effects and digital delivery options.

The DEMCARE trial supports NPIs as effective, low-risk interventions for AD. CST and music therapy improve QoL and reduce agitation, offering patient-centered care. Integration into community health services could enhance dementia management, particularly in early stages. Clinicians should prioritize NPIs alongside pharmacological options, tailoring interventions to patient needs.

Future research should investigate NPI mechanisms, such as neuroplasticity or social bonding, and evaluate scalability in diverse populations. Combining NPIs with caregiver training could amplify benefits, addressing global dementia burden as cases are projected to reach 152 million by 2050.

Text 2: Physiotherapy Interventions for Stroke Recovery

Authors: Michael L. Chen, PT, Ph.D., et al.

Published: June 6, 2025, Stroke

Stroke is a leading cause of disability, with 80% of survivors experiencing motor impairments like hemiparesis. Physiotherapy interventions, including task-oriented training (TOT) and robotic-assisted therapy (RAT), aim to restore motor function and independence. These approaches leverage neuroplasticity to improve outcomes, addressing limitations of conventional therapy, which often lacks intensity. The STROKE-REHAB trial evaluated TOT and RAT's efficacy in subacute stroke patients, focusing on scalable interventions to enhance rehabilitation access.

The STROKE-REHAB trial was a multicenter, randomized controlled trial involving 385 patients (mean age 62.4 years) within 3 months post-stroke. Participants received either TOT (daily functional tasks, 60 minutes, 5 days/week for 8 weeks), RAT (robotic arm exercises, same duration), or conventional therapy (standard exercises). The primary outcome was motor function, measured by Fugl-Meyer Assessment for Upper Extremity (FMA-UE, range 0–66). Secondary outcomes included activities of daily living (Barthel Index, BI), quality of life (Stroke Impact Scale, SIS), and therapy adherence.

At 8 weeks, TOT improved FMA-UE significantly (mean difference 6.3 points; 95% CI, 4.1–8.5; P=0.001) compared to conventional therapy. RAT showed a smaller improvement (mean difference 4.2 points; 95% CI, 2.0–6.4; P=0.01). BI scores increased in both TOT (mean difference 10.2; 95% CI, 6.8–13.6) and RAT (mean difference 7.5; 95% CI, 4.1–10.9), indicating better independence. SIS scores improved similarly (TOT: 8.1 points; RAT: 7.3 points). Adherence was high (92% TOT, 89% RAT), reflecting intervention feasibility.

Adverse events included muscle soreness (10.3% TOT, 12.1% RAT vs. 8.5% conventional) and transient fatigue (6.4% TOT, 7.8% RAT). No serious adverse events occurred. TOT's task-specific focus likely drove superior outcomes, while RAT's standardized delivery ensured consistency. Cost analysis showed TOT was more cost-effective (£1800 per FMA-UE point) than RAT (£2500), supporting broader adoption.

Subgroup analyses showed younger patients (<60 years) had greater FMA-UE gains with TOT (mean difference 7.8 vs. 4.5 for ≥60 years). Patients with moderate impairment (FMA-UE 20–40) benefited more than those with severe impairment (FMA-UE <20). Small subgroup sizes limit these findings' robustness, necessitating further study.

Strengths include trial's multicenter design and high adherence. Limitations include short follow-up (8 weeks) and exclusion of chronic stroke patients (>6 months), who may respond differently. RAT's high cost may restrict access in low-resource settings. Future studies should explore long-term outcomes and hybrid interventions.

The STROKE-REHAB trial supports TOT as a highly effective, cost-efficient intervention for subacute stroke recovery. RAT offers benefits but is less cost-effective. Physiotherapists should prioritize TOT, tailoring intensity to patient needs. Integration into rehabilitation programs could enhance stroke outcomes, particularly in early recovery.

Future research should investigate optimal intervention timing and combinations (e.g., TOT plus RAT). Long-term studies on functional independence and cost-effectiveness in diverse populations are needed, as stroke incidence rises globally. Digital tools, like tele-rehabilitation, could improve access, addressing barriers in underserved areas.